RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
@RobertoBurioni/ @Cartabellotta/ @lorepregliasco qualche commento in merito https://t.co/CiY8tBYP3O
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
The 1st peer-reviewed article on clinical trial of a COVID-19 vaccine at Lancet. https://t.co/Wh0oTta1uU
Es una fase I. Tranquilidad, pese a las expectativas. Ojalá progrese bien. https://t.co/GtQWAwCjOw El Lancet sobre la vacuna 👉 https://t.co/bFWwR6DRDi
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @ecapobianco: Some good news, to be taken with maximum caution, but still good news... #COVIDー19 @ifrc
RT @gorka_orive: Ensayo clínico fase I de #vacuna adenoviral frente a coronavirus (#COVID19) en >100 pacientes. La vacuna es segura (pocos…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
[Article] [Open access] La Ciencia va por buen camino en la lucha contra el #Covid_19 https://t.co/BSrEwrPmt6 https://t.co/BjNOtzbWxD
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @Covid_19Time: #COVID19 ☣️ 28 días después ✅ Vacuna 💉 tolerable e inmunogénica a los 28 días. Las respuestas alcanzaron su punto máximo…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/DGByWSkONv
No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination. https://t.c
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @Covid_19Time: #COVID19 ☣️ 28 días después ✅ Vacuna 💉 tolerable e inmunogénica a los 28 días. Las respuestas alcanzaron su punto máximo…
RT @FanLingXi: 柳叶刀文章,我们的疫苗! 🇨🇳🇨🇳🇨🇳 全人类的公共疫苗! 期待更多好消息!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @ecapobianco: Some good news, to be taken with maximum caution, but still good news... #COVIDー19 @ifrc https://t.co/ghlQhKFYUE
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @drjahanpur: مقاله ای در @TheLancet از موفقیت اولیه واکسن نوترکیب برای #کووید19 در ووهان خبر میدهد: فعلا تا قطعی شدن مطالعات و تولید انب…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @ecapobianco: Some good news, to be taken with maximum caution, but still good news... #COVIDー19 @ifrc
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @DanielMOrnelas: God I hope this vaccine doesn't have any old tweets. https://t.co/ZyLQeV3LK5
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
Resultados positivos en el ensayo (fase 1) de una vacuna contra el coronavirus que se está desarrollando en China. https://t.co/gmsDYH5CrL
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
E daje.... @RobertoBurioni
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/3FPFtgifGG
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @Covid_19Time: #COVID19 ☣️ 28 días después ✅ Vacuna 💉 tolerable e inmunogénica a los 28 días. Las respuestas alcanzaron su punto máximo…
RT @COVID19digest1: BREAKING -- First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response https://t.co/HkIvX…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @COVID19digest1: BREAKING -- First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response https://t.co/HkIvX…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @OACerebro: El primer ensayo de la #vacuna contra #COVIDー19: ▪️es segura ▪️induce una respuesta inmune rápida #BuenasNoticias First…
RT @MoNscience: .@TheLancet is dropping dimes this morning! First the hydroxychloroquine study... NOW: First human trial of COVID-19 vacci…
@Infocadl2015 @anthonyboerma @mus_nico @kakketoe @thierrybaudet Ik heb gewoon gerede hoop Kees. Zeker als dit soort serieuze media relevante informatie gaan publiceren. https://t.co/UZWyskuuSk
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @PRCAmbNL: Good news from the Chinese vaccine research team! Safe and effective vaccine development takes time, but we are making progr…
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @OlifaNT: Dear @chrismartenson, can you please shine a light on this vaccine study published in The Lancet today? Kind regards from The…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @gorka_orive: Ensayo clínico fase I de #vacuna adenoviral frente a coronavirus (#COVID19) en >100 pacientes. La vacuna es segura (pocos…
RT @DanielMOrnelas: God I hope this vaccine doesn't have any old tweets.
RT @MoNscience: .@TheLancet is dropping dimes this morning! First the hydroxychloroquine study... NOW: First human trial of COVID-19 vacci…
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @BiotechMania: 中国Cansino社のアデノウイルス5型ベクターCOVID-19ワクチンの初期臨床試験データがランセットに掲載。全身性重度有害事象(高熱等)の頻度が高く、アデノウイルスに対する中和抗体価が接種前から約半数で高いことから、論文の楽観的な結論と異…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
مقاله ای در @TheLancet از موفقیت اولیه واکسن نوترکیب برای #کووید19 در ووهان خبر میدهد: فعلا تا قطعی شدن مطالعات و تولید انبوه واکسن سعی کنید به #كرونا مبتلا نشوید! First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response h
First human trial of #COVID19 vaccine among 108 adults finds it is safe & produced neutralising antibodies & T-cell response against #SARSCoV2: Further research needed to confirm whether vaccine protects against #SARSCoV2 https://t.co/c5gkARhdl
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
While the number of subjects was very small, this looks hopeful https://t.co/SFq7xRKLKa
RT @gorka_orive: Ensayo clínico fase I de #vacuna adenoviral frente a coronavirus (#COVID19) en >100 pacientes. La vacuna es segura (pocos…
Recombinant adenovirus type-5 vectored #COVID19 vaccine (108 people, phase 1) • ~80% had at least one adverse reaction but no serious adverse event in 28 days • T-cell response peak at day 14, antibody peak at day 28 • Ad5 immunity could reduce effect http
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
PRIMER ESTUDIO SOBRE VACUNA #COVID-19 publicado (ECA fase 1) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/55C8wJ32FK
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
God I hope this vaccine doesn't have any old tweets.
RT @PRCAmbNL: Good news from the Chinese vaccine research team! Safe and effective vaccine development takes time, but we are making progr…
RT @FanLingXi: @CherryL10955185 帮你贴上柳叶刀推文https://t.co/yuy6IlFQQ4
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @COVID19digest1: BREAKING -- First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response https://t.co/HkIvX…
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…
RT @AniShakari: Good news! 💉 #COVOD19 Study of 108 adults finds the vaccine candidate well tolerated and produced neutralising antibodies…
RT @CarlosdelRio7: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @COVID19digest1: BREAKING -- First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response https://t.co/HkIvX…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @Covid_19Time: #COVID19 ☣️ 28 días después ✅ Vacuna 💉 tolerable e inmunogénica a los 28 días. Las respuestas alcanzaron su punto máximo…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @doctormacias: Un adenovirus modificado para expresar la proteína S del SARS-CoV-2 se usó como vacuna contra Covid-19. Un primer estudio…
RT @GilbertDeray: Une belle étude qui montre une réponse immunitaire chez 108 personnes après vaccination, sans effet secondaire. On avance…